Aurobindo Pharma Australia Pty Limited, the fully-owned subsidiary of Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), Aurobindo Pharma Limited, has received its first approval from the Therapeutic Goods Administration (TGA), Australia, for the registration of Auro-Lisinopril 5 mg, Auro-Lisinopril 10 mg and Auro-Lisinopril 20 mg tablets.
The approved indications for these therapeutic products are for treatment of hypertension, congestive heart failure and acute myocardial infraction, the company said in a filing to the BSE on Monday.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app